Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure

F. Lennie Wong, Smita Bhatia, Wendy Landier, Liton Francisco, Wendy Leisenring, Melissa M. Hudson, Gregory T. Armstrong, Ann Mertens, Marilyn Stovall, Leslie L. Robison, Gary H. Lyman, Steven E Lipshultz, Saro H. Armenian

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD. Objective: To evaluate the efficacy and cost-effectiveness of the COG guidelines and to identify more cost-effective screening strategies. Design: Simulation of life histories using Markov health states. Data Sources: Childhood Cancer Survivor Study; published literature. Target Population: Childhood cancer survivors. Time Horizon: Lifetime. Perspective: Societal. Intervention: Echocardiographic screening followed by angiotensinconverting enzyme (ACE) inhibitor and β-blocker therapies after ALVD diagnosis. Outcome Measures: Quality-Adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs) in dollars per QALY, and cumulative incidence of heart failure. Results of Base-Case Analysis: The COG guidelines versus no screening have an ICER of $61 500, extend life expectancy by 6 months and QALYs by 1.6 months, and reduce the cumulative incidence of heart failure by 18% at 30 years after cancer diagnosis. However, less frequent screenings are more cost-effective than the guidelines and maintain 80% of the health benefits. Results of Sensitivity Analysis: The ICER was most sensitive to the magnitude of ALVD treatment efficacy; higher treatment efficacy resulted in lower ICER. Limitation: Lifetime non-heart failure mortality and the cumulative incidence of heart failure more than 20 years after diagnosis were extrapolated; the efficacy of ACE inhibitor and -blocker therapy in childhood cancer survivors with ALVD is undetermined (or unknown). Conclusion: The COG guidelines could reduce the risk for heart failure in survivors at less than $100 000/QALY. Less frequent screening achieves most of the benefits and would be more costeffective than the COG guidelines. Primary Funding Source: Lance Armstrong Foundation and National Cancer Institute.

Original languageEnglish
Pages (from-to)672-683
Number of pages12
JournalAnnals of Internal Medicine
Volume160
Issue number10
DOIs
StatePublished - May 20 2014
Externally publishedYes

Fingerprint

Left Ventricular Dysfunction
Cost-Benefit Analysis
Survivors
Quality-Adjusted Life Years
Heart Failure
Guidelines
Neoplasms
Enzyme Inhibitors
Costs and Cost Analysis
Incidence
Therapeutics
National Cancer Institute (U.S.)
Health Services Needs and Demand
Information Storage and Retrieval
Anthracyclines
Insurance Benefits
Life Expectancy
Outcome Assessment (Health Care)
Mortality
Health

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. / Wong, F. Lennie; Bhatia, Smita; Landier, Wendy; Francisco, Liton; Leisenring, Wendy; Hudson, Melissa M.; Armstrong, Gregory T.; Mertens, Ann; Stovall, Marilyn; Robison, Leslie L.; Lyman, Gary H.; Lipshultz, Steven E; Armenian, Saro H.

In: Annals of Internal Medicine, Vol. 160, No. 10, 20.05.2014, p. 672-683.

Research output: Contribution to journalArticle

Wong, FL, Bhatia, S, Landier, W, Francisco, L, Leisenring, W, Hudson, MM, Armstrong, GT, Mertens, A, Stovall, M, Robison, LL, Lyman, GH, Lipshultz, SE & Armenian, SH 2014, 'Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure', Annals of Internal Medicine, vol. 160, no. 10, pp. 672-683. https://doi.org/10.7326/M13-2498
Wong, F. Lennie ; Bhatia, Smita ; Landier, Wendy ; Francisco, Liton ; Leisenring, Wendy ; Hudson, Melissa M. ; Armstrong, Gregory T. ; Mertens, Ann ; Stovall, Marilyn ; Robison, Leslie L. ; Lyman, Gary H. ; Lipshultz, Steven E ; Armenian, Saro H. / Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. In: Annals of Internal Medicine. 2014 ; Vol. 160, No. 10. pp. 672-683.
@article{ba4dcc1607f24607a13b6ecb5d9e054c,
title = "Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure",
abstract = "Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD. Objective: To evaluate the efficacy and cost-effectiveness of the COG guidelines and to identify more cost-effective screening strategies. Design: Simulation of life histories using Markov health states. Data Sources: Childhood Cancer Survivor Study; published literature. Target Population: Childhood cancer survivors. Time Horizon: Lifetime. Perspective: Societal. Intervention: Echocardiographic screening followed by angiotensinconverting enzyme (ACE) inhibitor and β-blocker therapies after ALVD diagnosis. Outcome Measures: Quality-Adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs) in dollars per QALY, and cumulative incidence of heart failure. Results of Base-Case Analysis: The COG guidelines versus no screening have an ICER of $61 500, extend life expectancy by 6 months and QALYs by 1.6 months, and reduce the cumulative incidence of heart failure by 18{\%} at 30 years after cancer diagnosis. However, less frequent screenings are more cost-effective than the guidelines and maintain 80{\%} of the health benefits. Results of Sensitivity Analysis: The ICER was most sensitive to the magnitude of ALVD treatment efficacy; higher treatment efficacy resulted in lower ICER. Limitation: Lifetime non-heart failure mortality and the cumulative incidence of heart failure more than 20 years after diagnosis were extrapolated; the efficacy of ACE inhibitor and -blocker therapy in childhood cancer survivors with ALVD is undetermined (or unknown). Conclusion: The COG guidelines could reduce the risk for heart failure in survivors at less than $100 000/QALY. Less frequent screening achieves most of the benefits and would be more costeffective than the COG guidelines. Primary Funding Source: Lance Armstrong Foundation and National Cancer Institute.",
author = "Wong, {F. Lennie} and Smita Bhatia and Wendy Landier and Liton Francisco and Wendy Leisenring and Hudson, {Melissa M.} and Armstrong, {Gregory T.} and Ann Mertens and Marilyn Stovall and Robison, {Leslie L.} and Lyman, {Gary H.} and Lipshultz, {Steven E} and Armenian, {Saro H.}",
year = "2014",
month = "5",
day = "20",
doi = "10.7326/M13-2498",
language = "English",
volume = "160",
pages = "672--683",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure

AU - Wong, F. Lennie

AU - Bhatia, Smita

AU - Landier, Wendy

AU - Francisco, Liton

AU - Leisenring, Wendy

AU - Hudson, Melissa M.

AU - Armstrong, Gregory T.

AU - Mertens, Ann

AU - Stovall, Marilyn

AU - Robison, Leslie L.

AU - Lyman, Gary H.

AU - Lipshultz, Steven E

AU - Armenian, Saro H.

PY - 2014/5/20

Y1 - 2014/5/20

N2 - Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD. Objective: To evaluate the efficacy and cost-effectiveness of the COG guidelines and to identify more cost-effective screening strategies. Design: Simulation of life histories using Markov health states. Data Sources: Childhood Cancer Survivor Study; published literature. Target Population: Childhood cancer survivors. Time Horizon: Lifetime. Perspective: Societal. Intervention: Echocardiographic screening followed by angiotensinconverting enzyme (ACE) inhibitor and β-blocker therapies after ALVD diagnosis. Outcome Measures: Quality-Adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs) in dollars per QALY, and cumulative incidence of heart failure. Results of Base-Case Analysis: The COG guidelines versus no screening have an ICER of $61 500, extend life expectancy by 6 months and QALYs by 1.6 months, and reduce the cumulative incidence of heart failure by 18% at 30 years after cancer diagnosis. However, less frequent screenings are more cost-effective than the guidelines and maintain 80% of the health benefits. Results of Sensitivity Analysis: The ICER was most sensitive to the magnitude of ALVD treatment efficacy; higher treatment efficacy resulted in lower ICER. Limitation: Lifetime non-heart failure mortality and the cumulative incidence of heart failure more than 20 years after diagnosis were extrapolated; the efficacy of ACE inhibitor and -blocker therapy in childhood cancer survivors with ALVD is undetermined (or unknown). Conclusion: The COG guidelines could reduce the risk for heart failure in survivors at less than $100 000/QALY. Less frequent screening achieves most of the benefits and would be more costeffective than the COG guidelines. Primary Funding Source: Lance Armstrong Foundation and National Cancer Institute.

AB - Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD. Objective: To evaluate the efficacy and cost-effectiveness of the COG guidelines and to identify more cost-effective screening strategies. Design: Simulation of life histories using Markov health states. Data Sources: Childhood Cancer Survivor Study; published literature. Target Population: Childhood cancer survivors. Time Horizon: Lifetime. Perspective: Societal. Intervention: Echocardiographic screening followed by angiotensinconverting enzyme (ACE) inhibitor and β-blocker therapies after ALVD diagnosis. Outcome Measures: Quality-Adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs) in dollars per QALY, and cumulative incidence of heart failure. Results of Base-Case Analysis: The COG guidelines versus no screening have an ICER of $61 500, extend life expectancy by 6 months and QALYs by 1.6 months, and reduce the cumulative incidence of heart failure by 18% at 30 years after cancer diagnosis. However, less frequent screenings are more cost-effective than the guidelines and maintain 80% of the health benefits. Results of Sensitivity Analysis: The ICER was most sensitive to the magnitude of ALVD treatment efficacy; higher treatment efficacy resulted in lower ICER. Limitation: Lifetime non-heart failure mortality and the cumulative incidence of heart failure more than 20 years after diagnosis were extrapolated; the efficacy of ACE inhibitor and -blocker therapy in childhood cancer survivors with ALVD is undetermined (or unknown). Conclusion: The COG guidelines could reduce the risk for heart failure in survivors at less than $100 000/QALY. Less frequent screening achieves most of the benefits and would be more costeffective than the COG guidelines. Primary Funding Source: Lance Armstrong Foundation and National Cancer Institute.

UR - http://www.scopus.com/inward/record.url?scp=84901277042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901277042&partnerID=8YFLogxK

U2 - 10.7326/M13-2498

DO - 10.7326/M13-2498

M3 - Article

C2 - 24842414

AN - SCOPUS:84901277042

VL - 160

SP - 672

EP - 683

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -